Immune checkpoint inhibitors can boost the immune system's response to tumor cells, but the medications tend to be ineffective against certain cancers, especially colorectal and pancreatic cancers. A new clinical trial led ...
Nov 18, 2021
0
7
Two new studies revealed that anti-PD-1 immunotherapy given before surgery was safe and effective for patients with oral-cavity squamous cell carcinoma (OCSCC) and identified potential molecular biomarkers in the blood and ...
Oct 29, 2021
0
10
MUSC Hollings Cancer Center researchers discovered a novel mechanism showing how a certain gene mutation can allow tumors to evade detection by the immune system in colorectal cancer patients. The study, which was published ...
Sep 2, 2021
0
25
Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical ...
Aug 16, 2021
0
18
In a small study of 16 patients with the rare cancer angiosarcoma, tumors in four patients partially or completely responded to treatment with a combination of the immunotherapy drugs ipilimumab and nivolumab. Another two ...
Aug 13, 2021
0
259
A prognostic scoring system that is cheap, efficient and reliable can predict how patients with relapsed and/or metastatic head and neck cancer will respond to immunotherapy, new research has shown.
Jul 22, 2021
0
5
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients ...
Jul 14, 2021
0
5
Many people don't realize that the trillions of bacteria, viruses, and fungi residing within the gastrointestinal tract—collectively called the gut microbiome—are connected to overall health, and specifically to cancer.
Jun 24, 2021
0
15
A new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients, a breakthrough that could extend to the treatment of other cancers. Relatlimab is the first immunotherapy treatment ...
Jun 3, 2021
0
6
A phase 3 clinical trial co-led by Mount Sinai researchers is the first to show that immunotherapy after surgery to remove bladder cancer can reduce the risk of relapse for patients who are at high risk of their cancer returning ...
Jun 2, 2021
0
2
